Ang is an important regulator of motor control, and AT1R and AT2R have been suggested as targets to combat Parkinson’s disease (PD) and related conditions such as levodopa (L-DOPA)-induced dyskinesias [38, 45]. Here, AGTR1 is linked to drug-induced dyskinesia.